IP Support for Investors
Overview
IP support for investors – due diligence, valuation, and how effective the protection really is
Do you invest in technology companies and want to know whether their intellectual property (IP) is worth what the pitch promises? We help VC funds, business angels and strategic investors assess IP the way you would assess any asset: does it really protect the competitive edge, will revenue projections built on exclusivity hold, and are there gaps that will become a problem at exit? We are a patent and trademark law firm, but we read IP through the lens of investment returns, not just legal status.
What role does IP play in an investment decision?
IP is rarely priority number one – market and team come first – but in industries where protection is critical (biotech, medtech, deep tech, hardware) it can be a binary gate: without it, the deal is off. The weight of IP grows over the company’s life cycle: moderate at seed, significant during growth, often decisive at exit. A separate signal is the founders’ “IP maturity” – whether they understand filing strategy, infringement risk and transfer of rights. We help you assess all of these dimensions, adjusted for European and Polish realities (a 2023 EPO/EUIPO study: with patents and trademarks in place, the chances of a successful exit can be several times higher).
Interested in working with us? Get in touch.
IP due diligence – what we actually check
Standard legal due diligence answers the question “are the rights valid and who owns them”. We add the question that matters more for returns: “does this IP actually block the competition the projections rely on?”. We check:
- legal title and its continuity (chain of title): transfer of rights from founders, employees and contractors, plus university-related issues,
- freedom to operate (FTO) and the risk of infringing third-party rights,
- portfolio quality: scope of the claims, prosecution history, resilience to invalidation,
- whether anyone actually wants to enter this market (is there anyone to exclude), and whether the company’s portfolio really blocks them or is easy to design around.
Will the IP provide real protection? An investor's perspective
We look at two dimensions: legal exclusivity (can the right be enforced, and against whom) and actual technical value (how quickly could a competitor copy the solution). A patent whose infringement cannot be detected (e.g. an algorithm running on a server), or one aimed at the company’s customers rather than its competitors, offers weak real-world protection – even though on paper it was properly granted. For AI, we add the “feature test”: could this product become a feature of a large model within a month? Where deep tech and hardware are what counts, a patent regains real weight. We help you establish which of these dimensions the company’s true advantage lies in.
Contact
Let's talk about protecting your brand
Tell us where you want to protect your name or logo. We'll prepare an action plan and a quote.
Support at every stage – from term sheet to exit
We match the scope to where you are in the deal:
- before the term sheet: a quick go/no-go IP assessment – is there anything in the portfolio that genuinely protects the investment thesis,
- after the term sheet: full IP due diligence with a report and a list of risks and conditions to closing,
- during the holding period: portfolio audits, monitoring, closing gaps,
- before exit: getting the IP ready for sale (clean title, FTO, gap analysis) so that it raises rather than lowers the valuation,
- IP-backed financing: assessing rights as collateral for debt investors and hybrid instruments.
Why EUPATENT – patent attorneys who think like investors
We combine the skills of patent attorneys with an investor’s perspective and founders’ operational experience. Most available due diligence and valuation frameworks are American – we translate them into European and Polish realities: EPO procedures and deadlines, oppositions, the first-to-file rule, the Unified Patent Court (UPC), and the specifics of the Polish Patent Office (UPRP) and the European Union Intellectual Property Office (EUIPO). You get an assessment grounded in the jurisdiction where your portfolio company actually competes.
FAQ
Frequently asked questions
IP due diligence checks whether a company's intellectual property really belongs to it and genuinely protects its competitive edge. It is usually done in two stages: a quick go/no-go assessment before the term sheet and a full review after signing, before the round closes. The later in the company's life cycle – especially before an exit – the more IP weighs. We tailor the scope to the stage of the deal.
IP is usually the third criterion – after market and team – but in industries such as biotech, medtech or deep tech it can be a binary condition: without it, the deal is off. Its weight grows with stage: moderate at seed, often decisive at exit. The founders' "IP maturity" is a separate signal. We help you judge whether IP actually matters in a given industry and at a given stage.
The most common are: unclear legal title (no written agreements transferring rights from founders, employees or contractors), the risk of infringing third-party rights (no freedom-to-operate analysis), and patents that are weak or impossible to enforce. Any of these can lower the valuation or stall the deal. We flag them early, together with a list of conditions to closing.
A patent protects only if its infringement can be detected and enforced against a competitor that has assets. A patent on a process hidden on a server, or one aimed at the customer rather than the competitor, gives weak real-world protection. We ask two questions: does anyone actually want to enter this market, and does the company's portfolio really block them – or is it easy to design around?
We start by establishing why the valuation is needed and which standard of value applies (market, fair, investment value for a specific buyer, or strategic) – mixing these concepts up is the source of most disputes. Then we select the method: cost, market (comparable transactions), income (DCF), real options or qualitative scoring, often combining several. The method follows the purpose: a funding round, an acquisition, a license or a dispute.
Yes – patents and trademarks are sometimes used as collateral, especially in debt financing and hybrid instruments. The condition is strict, though: the right needs a credible valuation and must be enforceable, otherwise it is worth little as security. We assess which rights in a portfolio are actually fit for this. It is still a niche, but a growing one.
Freedom to operate (FTO) is an analysis of whether the company can sell its product without infringing third-party rights. It is not the same as owning patents – you can hold your own patent and still infringe someone else's. The risk is serious: the consequences can include a sales ban or costly litigation. That is why an FTO search is one of the key elements of pre-investment due diligence.
Not necessarily. You need to check whether the patent has actually been granted or merely applied for, how broad its scope is (the claims) and in which countries it is in force. A narrow patent that is easy to design around gives little protection, however impressive it sounds. Quality matters, not the mere fact of having one. We verify the real scope and strength of the protection, not just its existence.
Clean, strong IP raises the valuation and speeds up the deal because it takes risk off the buyer; gaps do the opposite and often become an excuse to argue the price down. A 2023 study by the EPO and the EUIPO showed that companies holding patents and trademarks were more than three times as likely to achieve a successful exit. That is why IP is worth preparing before an exit: clean title, freedom to operate, gap analysis. We support portfolio companies in exactly that.
There are quite a few differences, and they affect risk. Europe has no grace period – an earlier disclosure destroys the patent, and what counts is who files first; there are also opposition proceedings and the Unified Patent Court (UPC). Many off-the-shelf due diligence and valuation tools are American and do not account for these realities. We assess IP in the jurisdiction where your portfolio company actually operates.